Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.83 Average Price Target from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has received a consensus recommendation of “Buy” from the seven ...